Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する実験動画

ハイパーカリエミアと化学療法

F M Muggia

    Lancet (London, England)
    |March 17, 1973
    PubMed
    まとめ

    No abstract available in PubMed .

    関連する実験動画

    関連する概念動画

    こちらも読む

    関連記事

    共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

    並び替え
    Same author

    A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial carcinoma of the uterus.

    Gynecologic oncology·2024
    Same author

    BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups.

    Annals of oncology : official journal of the European Society for Medical Oncology·2013
    Same author

    Brain metastases from choriocarcinoma: two patients illustrating key management issues.

    Journal of chemotherapy (Florence, Italy)·2008
    Same author

    Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2005
    Same author

    Platinums: extending their therapeutic spectrum.

    Journal of chemotherapy (Florence, Italy)·2005
    Same author

    'Retarded pharmaceuticals' assuming a clinical role.

    Onkologie·2004
    Same journal

    Assisted dying and the silencing of medicine's next generation.

    Lancet (London, England)·2026
    Same journal

    Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

    Lancet (London, England)·2026
    Same journal

    Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

    Lancet (London, England)·2026
    Same journal

    [<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

    Lancet (London, England)·2026
    Same journal

    Research priorities for characterising Bundibugyo virus.

    Lancet (London, England)·2026
    Same journal

    Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

    Lancet (London, England)·2026
    関連記事をすべて見る